(Q34729771)

English

Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

multicenter clinical trial

0 references

urinary tract infection

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Mattina R

1

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Cocuzza CE

2

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Cesana M

3

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

publication date

1 March 1993

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

106-111

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Comparative study using norfloxacin and amoxycillin in the treatment of complicated urinary tract infections in geriatric patients

1 reference

https://api.crossref.org/works/10.1007%2FBF01710743

21 January 2018

Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1007%2FBF01710743

21 January 2018

Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers

1 reference

https://api.crossref.org/works/10.1007%2FBF01710743

21 January 2018

Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin

1 reference

https://api.crossref.org/works/10.1007%2FBF01710743

21 January 2018

Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital

1 reference

https://api.crossref.org/works/10.1007%2FBF01710743

21 January 2018

Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections

1 reference

https://api.crossref.org/works/10.1007%2FBF01710743

21 January 2018

Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers

1 reference

https://api.crossref.org/works/10.1007%2FBF01710743

21 January 2018

The Garrod lecture. Progress in understanding urinary infections

1 reference

https://pubmed.ncbi.nlm.nih.gov/8387963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Norfloxacin treatment in complicated urinary tract infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/8387963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ofloxacin in urinary tract infections

1 reference

https://pubmed.ncbi.nlm.nih.gov/8387963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluoroquinolone antimicrobial agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/8387963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/8387963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rufloxacin (MF-934): in vitro and in vivo antibacterial activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/8387963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety profile of quinolones

1 reference

https://pubmed.ncbi.nlm.nih.gov/8387963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro Activity of a New Quinolone, Rufloxacin, against Nosocomial Isolates

1 reference

https://pubmed.ncbi.nlm.nih.gov/8387963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of rufloxacin in healthy volunteers after repeated oral doses

1 reference

https://pubmed.ncbi.nlm.nih.gov/8387963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disk susceptibility of ofloxacin, a new carboxyquinolone

1 reference

https://pubmed.ncbi.nlm.nih.gov/8387963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Comparative studies of DL-8280 and pipemidic acid in complicated urinary tract infections by double-blind method]

1 reference

https://pubmed.ncbi.nlm.nih.gov/8387963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methicillin-resistant strains of Staphylococcus aureus resistant to quinolones.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8387963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multicenter study on clinical efficacy of ofloxacin in respiratory and urinary tract infections

1 reference

https://pubmed.ncbi.nlm.nih.gov/8387963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An open multicentre study on the efficacy and safety of rufloxacin in patients with chronic bacterial prostatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/8387963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative studies of fluoroquinolones in the treatment of urinary tract infections

1 reference

https://pubmed.ncbi.nlm.nih.gov/8387963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids

1 reference

https://pubmed.ncbi.nlm.nih.gov/8387963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Side-effects of quinolones: Comparisons between quinolones and other antibiotics

1 reference

https://pubmed.ncbi.nlm.nih.gov/8387963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Parenteral ciprofloxacin compared with ceftazidime in the treatment of serious upper and lower urinary tract infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/8387963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8387963

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF01710743

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34729771&oldid=2196987396"